Predictive biomarkers of response to adalimumab treatment in patients with hidradenitis suppurativa

Abstract

British Journal of DermatologyVolume 185, Issue 4 p. e160-e160 Plain Language Summary Predictive biomarkers of response to adalimumab treatment in patients with hidradenitis suppurativa First published: 04 October 2021 https://doi.org/10.1111/bjd.20670AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Cao et al. Br J Dermatol 2021; 185:804–814. Hidradenitis suppurativa (HS), also known as acne inversa, is a long-lasting, inflammatory skin disease resulting in painful lesions in and around the sweat glands. It is a common disease but the average delay in accurate diagnosis is 7 years from first signs of disease. Currently, adalimumab is the only drug approved by the US Food and Drug Administration and the European Medicines Agency for treating HS. In recent clinical trials adalimumab was found to be beneficial in more than 50% of patients with HS. Our study, from the USA, aimed to identify certain proteins in the blood that can predict whether a patient with HS will respond to adalimumab as well as potentially understand the difference between patients who improve with adalimumab and those that do not. To do this, we measured levels of several specific circulating proteins before patients received adalimumab and after 12 weeks of treatment in clinical trials of the drug. We found that even before beginning adalimumab therapy, certain proteins associated with inflammatory diseases were lower in patients who showed disease improvement. In addition, patients who improved while being treated with adalimumab showed a greater reduction in specific proteins that promote inflammation. From these results, we were able to find a combination of proteins measured prior to adalimumab therapy that together could identify a large portion of patients that would improve with treatment. In conclusion, we identified a set of specific blood proteins that could determine which patients with HS will benefit from treatment with adalimumab. Although further testing and development is needed, this set of blood proteins could be used in the future to help physicians determine which therapy would be best for patients with HS. Volume185, Issue4October 2021Pages e160-e160 RelatedInformation